$8 million grant funds development of NXC-201 in relapsed/refractory AL AmyloidosisLOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix…
BOULDER, Colo., July 25, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced that Dylan Hartley, Ph.D. has been appointed to…
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics…
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced it will report second quarter…
ALL represents 10% of all leukemia cases in the United States, progresses rapidly, and is typically fatal within weeks or…
VANCOUVER, British Columbia, July 25, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse…
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic…
BASEL, Switzerland and LONDON and NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it…
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncology programs as promising clinical…
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development…